At ASGCT 2025, Stylus had an oral presentation on its engineering high-efficiency, high-specificity recombinases for in vivo engineering. The company reported engineering high-efficiency, high-specificity recombinases targeted to a novel safe harbour site in the human genome. The company's engineered recombinases act without the use of landing pads, protein fusions, or guide RNAs and possess a well-defined integration profile. These proprietary recombinases serve as the foundation of Stylus' in vivo genetic medicines platform, which features single-step insertion of multi-kb therapeutic payloads.
They also presented data on its in vivo CAR-T platform, which combines a proprietary recombinase that enables sequence-specific genome integration with cell-targeted lipid nanoparticle (LNP) delivery.
Market Data 
Markets 
AI
